Richard Conway RichardPAConway
3 years 10 months ago
Katz @GuyKatzMD et al. Coronary involvement in IgG4-RD. 13 cases, all male, median 11 years disease. All elevated serum IgG4. Aneurysms 8/13, arteritis 9/13 periarteritis 11/13. @RheumNow #ACR22 Abstr#1571 https://t.co/At7Gw2kRUp https://t.co/zcXc6oUS0f
Dr. Rachel Tate uptoTate
3 years 10 months ago
BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV
Richard Conway RichardPAConway
3 years 10 months ago
Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Patricia Harkins DrTrishHarkins
3 years 10 months ago
Congenital ❤️ Block in Ro/La pregnancies
Abst#0957
👉1st echo @ mean 20wk
👉CHB 3/47- all on 1st echo
👉 1 reversed 3rd ➡️ 1st AVB post dexamethasone
🔥Key messages🔥
🤰serial echo should start @ 16-18wk gestation
👶 early detection ⬆️ outcomes
#ACR22 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 10 months ago
#ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD per month) affects adherence to treatment (HCQ, AZA, MMF but not MTX) in #lupus @RheumNow https://t.co/WnwIhpqDxL
Is there finally something new on the horizon in Sjogren’s syndrome?
David Liew drdavidliew
3 years 10 months ago
"If I had one test in a difficult case of suspected PMR, it would be PET/CT" - @LCalabreseDO
#ACR22 @RheumNow
(credit: as heard by @drceowen) https://t.co/w88peUd4j1
Patricia Harkins DrTrishHarkins
3 years 10 months ago
Mx aging rheumatic dx pt
🌟5M approach🌟
🧠Mind (mood/cog)
💊 Medication (polypharm)
🏃 Mobility
👉Multicomplexity (biopsychsoc)
💪🏻 Matters (aligning 2 specific goals)
💥Interdisciplinary💥
#GeriRheum #ACR22 @RheumNow @B_Buehring_MD @UnaMakris
Dr. Rachel Tate uptoTate
3 years 10 months ago
DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 10 months ago
#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY
Mike Putman EBRheum
3 years 10 months ago
Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS
Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain)
Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited
#ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR
Fabio Torres FabioTorressav
3 years 10 months ago
@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis.
Certain HLA haplotypes more linked with autoimmune diseases are present.
#ACR
@RheumNow
Dr. Rachel Tate uptoTate
3 years 10 months ago
Presence of DFS pattern should not be used to indiscriminately exclude presence of a rheumatic disease based on retrospective study in Abs 0814. RA, SS and Raynaud's ICD10 codes were higher among DFS pattern ANA per chart review. #ACR22 @RheumNow https://t.co/mLtppvR4dk https://t.co/6Lukxntqe7
